Commercial dynamics and outlook of the neurology, pain and psychiatry market sectors

The market for CNS drugs across the 7MM was worth a substantial $95.5 billion, accounting for a 21.4% share of the total pharmaceutical market value in 2007. Despite stalling R&D productivity and the genericization of the majority of leading CNS blockbuster brands, the market continues to offer a wealth of lucrative opportunities for all types of drug manufacturer.

On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology.

Currently dominated by Big Pharma players and a number of multi-blockbuster antidepressant and antipsychotic brands, the psychiatry market value will begin to decrease from 2010 onwards as key patents begin to expire. Nevertheless, continued investment will eventually see the R&D pipeline yield new improved agents with blockbuster potential.

Read more...

• Cardiovascular Disease (CVD) Market (15/03/2010)
• Pain Market Overview (19/02/2010)
• Pain Management Market Outlook (19/02/2010)

• Pricing and Reimbursement in the UAE (08/05/2009)
• Future Pharmaceutical Industry Trends (17/04/2009)
• Generic Benchmarking (17/04/2009)
• Tuberculosis (07/04/2009)
• Healthcare Technology Opportunities (30/03/2009)
• Generics Trends in the Seven Major Markets (20/03/2009)
• M&A trends in Pharma (13/03/2009)
• Pharmaceutical Company Outlook (13/03/2009)
• Biosimilars: Strategic issues (06/03/2009)

---